Michael P.Clark, Mark W.Ledeboer, IoanaDavies, Randal A.Byrn, Steven M.Jones, EmanuelePerola, AliceTsai, MarcJacobs, KwameNti-Addae, Upul K.Bandarage, Michael J.Boyd, Randy S.Bethiel, John J.Court, HongboDeng, John P.Duffy, Warren A.Dorsch, Luc J.Farmer, HuaiGao, WenxinGu, KatrinaJackson, Dylan H.Jacobs, Joseph M.Kennedy, BrianLedford, JianglinLiang, FrançoisMaltais, MarkMurcko, TianshengWang, M. WoodsWannamaker, Hamilton B.Bennett, Joshua R.Leeman, ColleenMcNeil, William P.Taylor, ChristineMemmott, MinJiang, ReneRijnbrand, ChristopherBral, UrsulaGermann, AzinNezami, YuegangZhang, Francesco G.Salituro, Youssef L.Bennani, Paul S.Charifson. (2014) Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2. Journal of Medicinal Chemistry 57, 6668-6678
CrossRef